Recent developments include the announcement of Viatris's acquisition of Pacira for $1.65 billion, expansion of EXPAREL's commercial reach in Europe through a partnership with Molteni, and ongoing clinical and regulatory progress for key products and pipeline candidates.

• In October 2026, Viatris announced a $1.65 billion cash acquisition of Pacira BioSciences to expand its non-opioid pain portfolio [N2,N4].
• Pacira's stock rose 44% on acquisition news, reflecting market reaction to the deal [N3].
• In October 2026, Pacira expanded EXPAREL's commercial reach in Europe through an exclusive partnership with Molteni Farmaceutici, receiving upfront payments and royalties; Molteni plans launches in multiple European countries starting in 2027 [N5].
• Pacira reported upcoming earnings with expectations of earnings growth [N1].
• Pacira's gene therapy candidate PCRX-1001 qualified for the FDA's Veterinary Innovation Program in October 2026 [S2].

Pacira's innovative non-opioid pain management products, including EXPAREL and ZILRETTA, address large markets with unmet needs, supported by strong clinical data and regulatory approvals. The advancement of PCRX-201 gene therapy with promising Phase 1 results and ongoing Phase 2 trials highlights potential for a novel, durable OA treatment. Strategic partnerships in Asia-Pacific and Europe expand commercial reach. The pending acquisition by Viatris could provide additional resources and integration opportunities to accelerate growth and broaden market access.

Pacira faces risks from global economic volatility, including tariffs and supply chain disruptions that could increase costs and impact margins. Regulatory uncertainties and the complexity of advancing gene therapy candidates pose development risks. The competitive landscape for pain management therapies is evolving, and market adoption of new products may be slower than anticipated. Integration risks exist related to the pending acquisition by Viatris. Manufacturing scale-up and patent expirations could also affect competitive positioning and financial performance.

Pacira's moat is supported by its proprietary drug delivery technology platform underlying EXPAREL, a portfolio of 23 patents protecting EXPAREL's composition with expiration dates extending to 2044, and its unique gene therapy HCAd vector platform enabling novel treatments like PCRX-201. Its established commercial presence with differentiated non-opioid pain therapies and strategic partnerships expanding geographic reach further strengthen its competitive position. The company's focus on opioid-sparing therapies addresses significant unmet medical needs, supported by clinical data and real-world evidence from its IGOR registry. Manufacturing scale-up and intellectual property protection contribute to barriers against competitors.

• Global Economic and Tariff Risks: Volatility in global economic conditions, inflation, and tariffs on pharmaceutical imports could increase manufacturing and operating costs, disrupt supply chains, and negatively impact revenues and margins [S1,S2].
• Regulatory and Development Risks: Advancement of gene therapy candidates like PCRX-201 involves regulatory uncertainties and clinical development risks that could affect timelines and outcomes [S1,S2].
• Acquisition and Integration Risks: The pending acquisition by Viatris presents risks related to integration, potential changes in strategic direction, and execution challenges [N2,N4].
• Competitive and Market Risks: Competition in non-opioid pain management and OA treatments may impact market share and pricing. Adoption of new therapies depends on physician and payer acceptance [S1,S2].

• Pacira BioSciences, Inc. develops and commercializes non-opioid pain therapies including EXPAREL, ZILRETTA, and iovera® system, targeting postsurgical pain and osteoarthritis (OA) pain management [S1].
• EXPAREL is a long-acting local analgesic using proprietary pMVL drug delivery technology, approved for local and regional analgesia in patients aged six years and older in the U.S., and for certain indications in Europe [S1,S2].
• ZILRETTA is an extended-release corticosteroid intra-articular injection for OA knee pain, approved in the U.S. since 2017, with ongoing clinical studies for OA shoulder pain [S1,S2].
• The iovera® system is a handheld cryoanalgesia device delivering controlled cold temperature to targeted nerves, sold directly to end users [S1].
• Pacira is advancing PCRX-201, a gene therapy candidate for OA knee pain using its proprietary HCAd vector platform, which has shown encouraging Phase 1 data with pain relief lasting at least two years from a single injection and is in Phase 2 clinical trials [S1,S2].
• The company completed acquisitions of Flexion Therapeutics (ZILRETTA) in 2021 and GQ Bio Therapeutics GmbH (PCRX-201 platform) in 2025 [S1].
• Pacira has strategic partnerships to expand commercial reach of EXPAREL in Asia-Pacific with LG Chem and in Europe with Molteni Farmaceutici, involving upfront payments, royalties, and regulatory responsibilities [S1,S2,N5].
• In 2026, Pacira announced a pending acquisition by Viatris Inc. for $1.65 billion in cash, aiming to expand Viatris's non-opioid pain portfolio [N2,N4].
• Pacira's manufacturing includes facilities in San Diego, California, and contract manufacturing in the UK; active pharmaceutical ingredients for key products are sourced primarily from the EU and Switzerland [S1,S2].
• The company has a share repurchase program authorized up to $300 million, with repurchases made in late 2025 [S1].
• Pacira reported cash and equivalents of approximately $247 million and short-term investments of $48.6 million as of September 30, 2026, with a strong liquidity position including a current ratio of 4.68 and cash ratio of 2.34 [S2].
• Pacira faces risks related to global economic conditions, tariffs, supply chain disruptions, and regulatory uncertainties, including recent U.S. tariffs on pharmaceutical imports and ongoing trade policy volatility [S1,S2].
• The company has a portfolio of 23 patents for EXPAREL listed in the FDA Orange Book with expiration dates between 2041 and 2044 [S2].
• Pacira's clinical registry IGOR collects real-world data on OA treatments including ZILRETTA and EXPAREL to support clinical development and outcomes research [S1].
• Pacira's Q3 2026 financials show net income of $28.5 million and basic EPS of $0.72 [S2].
• Pacira's products are positioned as opioid-sparing therapies addressing significant unmet needs in postsurgical and OA pain management [S1,S2].